These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16127709)

  • 1. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
    Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
    J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
    Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
    Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
    Popovic N; Maingay M; Kirik D; Brundin P
    Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
    Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Menalled LB; Sison JD; Dragatsis I; Zeitlin S; Chesselet MF
    J Comp Neurol; 2003 Oct; 465(1):11-26. PubMed ID: 12926013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset.
    Vatsavayai SC; Dallérac GM; Milnerwood AJ; Cummings DM; Rezaie P; Murphy KP; Hirst MC
    Brain Res Bull; 2007 Apr; 72(2-3):98-102. PubMed ID: 17352932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
    Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
    J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
    Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
    Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
    Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
    Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
    Hernández-Espinosa D; Morton AJ
    Brain Res Bull; 2006 May; 69(6):669-79. PubMed ID: 16716837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ; Manley K; Messer A
    Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.